Mesoblast, an Australia-listed regenerative medicine company, has raised A$170m ($150m) in a private placement of shares including to its “existing strategic investors”.
Under the placement, 27 million ordinary shares, 9.4%, were issued at A$6.30 each, a discount of 2.2% to the closing price of the company’s shares on 1 March.
However, Mesoblast’s spokeswoman by email said drugs group “Teva did not participate in the placement but retains its current shareholding”.